Li Xiao-Lei, Zheng Zhi-Jian, Qu Hai-Ou
Department of Breast Surgery, First People's Hospital of Wenling, P.R. China.
Department of Breast Surgery, First People's Hospital of Wenling, P.R. China
J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1095-100. doi: 10.1177/1470320314529357. Epub 2014 Jun 24.
Previous case-control studies on the relation between angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and breast cancer did not reach the same conclusion. In the present study, we aimed to further evaluate the relationship between the ACE gene I/D polymorphism and breast cancer.
We selected 13 case-control studies related to ACE gene I/D polymorphism and breast cancer by searching PubMed, EMBase, Chinese Biomedical Literature Database, Chinese CNKI, and Wanfang database. To test the heterogeneity between each study, we utilized the Q-test and I(2) test. To merge the odds ratio (OR) and 95% confidence interval (CI), we utilized the random effects model during the analyses.
The present study included 1997 patients with breast cancer and 8404 cancer-free control subjects. By meta-analysis, we did not find any association of ACE gene I/D polymorphism with breast cancer in different model (DD vs (ID+II): OR=1.28, 95% CI (0.90-1.81), p=0.16; II vs (ID+DD): OR=0.99, 95% CI (0.81-1.21), p=0.93; D allele vs I allele: OR=1.15, 95% CI (0.94-1.41), p=0.18).
We concluded that ACE gene I/D polymorphism was not associated with breast cancer.
既往关于血管紧张素转换酶(ACE)基因插入/缺失(I/D)多态性与乳腺癌关系的病例对照研究未得出相同结论。在本研究中,我们旨在进一步评估ACE基因I/D多态性与乳腺癌之间的关系。
通过检索PubMed、EMBase、中国生物医学文献数据库、中国知网和万方数据库,我们选取了13项与ACE基因I/D多态性和乳腺癌相关的病例对照研究。为检验各研究之间的异质性,我们采用了Q检验和I²检验。在分析过程中,我们采用随机效应模型合并比值比(OR)和95%置信区间(CI)。
本研究纳入了1997例乳腺癌患者和8404例无癌对照者。通过荟萃分析,我们发现在不同模型中,ACE基因I/D多态性与乳腺癌均无关联(DD vs (ID + II):OR = 1.28,95% CI (0.90 - 1.81),p = 0.16;II vs (ID + DD):OR = 0.99,95% CI (0.81 - 1.21),p = 0.93;D等位基因vs I等位基因:OR = 1.15,95% CI (0.94 - 1.41),p = 0.18)。
我们得出结论,ACE基因I/D多态性与乳腺癌无关。